Europe’s medical devices industry sees a flat growth in deal activity in Q4 2020

27 January 2021 (Last Updated January 27th, 2021 17:10)

Europe’s medical devices industry sees a flat growth in deal activity in Q4 2020

Europe’s medical devices industry saw a flat growth in overall deal activity during Q4 2020, when compared to the four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 94 deals worth $1.75bn were announced for the region during Q4 2020, against the last four-quarter average of 94 deals.

Of all the deal types, venture financing saw most activity in Q4 2020 with 46, representing a 48.9% share for the region.

In second place was M&A with 37 deals, followed by private equity deals with 11 transactions, respectively capturing a 39.4% and 11.7% share of the overall deal activity for the quarter.

In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $982.99m, while private equity and venture financing deals totalled $415.46m and $353.3m, respectively.

Europe medical devices industry deals in Q4 2020: Top deals

The top five medical devices deals accounted for 69.3% of the overall value during Q4 2020.

The combined value of the top five medical devices deals stood at $1.21bn, against the overall value of $1.75bn recorded for the quarter.

The top five medical devices industry deals of Q4 2020 tracked by GlobalData were:

1) Exact Sciences’ $410m acquisition of Base Genomics

2) The $286.77m private equity deal with Bioneb by GEM Global YieldSCS

3) Richter Gedeon Nyrt’s $263.5m asset transaction with Janssen Pharmaceutica

4) The $143.81m acquisition of Cranach Pharma by Medios

5) ACE &SA, Alychlo, aMoon Partners, Credit Suisse Group, Endeavour Vision, Eurazeo Growth, Famille C Invest, Generation Investment Management, Hitachi Ventures, Pictet & Cie Group and Swisscom Ventures’ venture financing of Sophia Genetics for $110m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.